ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations

ORIC-114 - ORIC Pharma, Voronoi

zipalertinib (CLN-081) - Cullinan Therap, Otsuka

Ivesa (firmonertinib) - Allist, ArriVent

BDTX-1535 - Black Diamond Therap

https://cm.eortc.org/cmPortal/Searchable/ena2024/config/Normal#!abstractdetails/0000966340

M. Junttila 1; C.E. Repellin 1; R. Warne 1; J.E. Long 1; L. Sambucetti 1; P. Ashley 1; G. Andreatta 1; J. Baik 1; S. Salaniwal 1; C. Colas 1; A. Romero 1; L. Soroceanu 1; R. Patel 2; E. Chow Maneval 2; P.S. Multani 2; A. Daemen 1; L. Friedman 1

Sep 8, 2024